Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06317675
Other study ID # ct9873
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 18, 2024
Est. completion date April 2026

Study information

Verified date March 2024
Source Studio Osteopatico Busto Arsizio
Contact Carolina Lavazza
Phone +39 02 96701013
Email carolina.lavazza@docenti.aimoedu.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effects of osteopathic manipulative treatment in patients affected by symptoms related to gastro-oesophageal reflux disease (GERD)


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Retrosternal burning sensation and/or regurgitation - Diagnosis of reflux with any methodology - Duration of symptoms for more than 3 months - Taking short or long-term proton pump inhibitors (as needed, treatment start date and expected end date, mg, drug name) - With or without esophagitis - With or without hiatal hernia - With or without helicobacter pylori - GERDQ questionnaire > 8 points Exclusion Criteria: - neoplastic pathologies - patients who have undergone surgery for GERD - systemic pathologies (rheumatic, infectious conditions, feverish state, vascular alterations, endocrine diseases including diabetes, metabolic and neoplastic syndromes), - patients already undergoing manipulative therapy for reflux - patients with active gastric ulcers - congenital or acquired immune diseases - allergic state of any kind - pregnancy - use of intrauterine device - patients undergoing corticosteroid therapy - patients already subjected to manual/respiratory therapy in the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Osteopathic manipulative treatment (OMT)
Manual therapy on different area of the body.

Locations

Country Name City State
Italy CTFO Saronno Varese

Sponsors (1)

Lead Sponsor Collaborator
Studio Osteopatico Busto Arsizio

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in GERD-HRQL best possible score: 0, worst possible score: 50 At week 2, 4 an 8.
Primary Adverse effects Type and number. At week 2, 4 and through study completion (8 weeks)
Secondary Exercise adherence number of exercises per day performed by participants in OMT + exercise group. through study completion (8 weeks)
Secondary Change in drugs use Types, number and frequency of drug assumptions (such as PPI and other oral suspensions) At week 2, 4 and 8.
See also
  Status Clinical Trial Phase
Completed NCT00384592 - PPI Sequencing Study Phase 4
Completed NCT03793556 - Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor N/A
Completed NCT01507298 - Physical Activity and Gastrointestinal Investigations